GlassScriptPhysician profile
Jasmine D Usher Ledet
NPI 1376794263
$3,520.23
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $753 · 2021: $913 · 2022: $861.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.10 | 2021-2022 | |
| Pfizer INC. | $440.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $422.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $313.24 | 2019-2022 | |
| Novo Nordisk INC | $280.93 | 2019-2022 | |
| Allergan, INC. | $211.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $175.81 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $154.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.26 | 2022 | |
| Lilly USA, LLC | $113.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.16 | 2019-2022 | |
| Amgen INC. | $74.40 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $69.19 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $56.29 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $48.15 | 2020-2022 | |
| Astellas Pharma US INC | $42.43 | 2019-2021 | |
| Grifols USA, LLC | $42.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.54 | 2020-2021 | |
| Eisai INC. | $16.46 | 2021 | |
| Bioventus LLC | $16.05 | 2019 | |
| Circassia INC. | $14.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.76 | 2021 | |
| Sanofi Pasteur INC. | $12.52 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Usher Ledet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.